Zynteglo

TIF.ACCESS: A Global TIF Initiative for the Promotion of the Availability & Accessibility of Innovative Therapies
NOVITÀ

TIF.ACCESS: A Global TIF Initiative for the Promotion of the Availability & Accessibility of Innovative Therapies

The swift scientific progress made in the field of thalassaemia research has gained momentum with the market authorisations of both the Zynteglo Gene Therapy by the European Medicines Agency (EMA)…
Gene Therapy & Thalassaemia: A TIF Survey
Surveys

Gene Therapy & Thalassaemia: A TIF Survey

Millions of people worldwide suffer from inherited non-malignant blood disorders like thalassaemia and sickle cell disease. The culprit: genetic defects in their blood stem cells. One of the novel therapies …
Explaining Gene Therapy in thalassaemia (2020)
Publications

Explaining Gene Therapy in thalassaemia (2020)

The second educational brochure from the TIF’s ‘Gene Therapy’ booklet series, providing an in-depth view of how this revolutionary therapy works in patients with β-thalassaemia major.
TIF ITD2020 Webinar: The Patients’ Perspective on the Accessibility & Affordability of Novel Therapies for Thalassaemia
NOVITÀ

TIF ITD2020 Webinar: The Patients’ Perspective on the Accessibility & Affordability of Novel Therapies for Thalassaemia

9 patients with thalassaemia, members of TIF’s Patient Advocacy Group for Thalassaemia and Sickle Cell Disease (T-PAG), are discussing with the Thalassaemia International Federation the accessibility and affordability of the…
Back to top button